We are live on ! Find out more
FBT icon

First Trust NYSE Arca Biotechnology Index Fund

93 hedge funds and large institutions have $724M invested in First Trust NYSE Arca Biotechnology Index Fund in 2014 Q2 according to their latest regulatory filings, with 16 funds opening new positions, 46 increasing their positions, 25 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

129% more first-time investments, than exits

New positions opened: 16 | Existing positions closed: 7

84% more repeat investments, than reductions

Existing positions increased: 46 | Existing positions reduced: 25

13% more capital invested

Capital invested by funds: $639M → $724M (+$84.2M)

11% more funds holding

Funds holding: 8493 (+9)

1.04% more ownership

Funds ownership: 54.51%55.55% (+1%)

12% less call options, than puts

Call options by funds: $2.12M | Put options by funds: $2.42M

33% less funds holding in top 10

Funds holding in top 10: 32 (-1)

Holders
93
Holders Change
+9
Holders Change %
+10.71%
% of All Funds
2.66%
Holding in Top 10
2
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-33.33%
% of All Funds
0.06%
New
16
Increased
46
Reduced
25
Closed
7
Calls
$2.12M
Puts
$2.42M
Net Calls
-$296K
Net Calls Change
+$4.98M

FBT Hedge Fund Activity: Q2 2014 in Review

93 of the 3,491 institutional investors tracked by Wall St. Rank reported a position in First Trust NYSE Arca Biotechnology Index Fund (FBT) for Q2 2014, worth a combined $724M — up 13% from $639M a quarter earlier.

Buyers outnumbered sellers: 16 funds opened new FBT positions and 7 closed out — a net gain of 9 holders — while 46 added to existing stakes and 25 trimmed.

The largest buyer was First Trust Advisors, adding an estimated $45.2M. The largest seller was Goldman Sachs, cutting an estimated $34.9M.

  • 93 institutional investors held First Trust NYSE Arca Biotechnology Index Fund (FBT) as of Q2 2014, up from 84 in Q1 2014.
  • Funds reported $724M of First Trust NYSE Arca Biotechnology Index Fund stock for Q2 2014, up 13% quarter-over-quarter.
  • 16 funds opened new First Trust NYSE Arca Biotechnology Index Fund positions in Q2 2014 and 7 closed out, a net change of +9 holders.
  • The largest First Trust NYSE Arca Biotechnology Index Fund buyer in Q2 2014 was First Trust Advisors, an estimated $45.2M added.
  • The largest First Trust NYSE Arca Biotechnology Index Fund seller in Q2 2014 was Goldman Sachs, an estimated $34.9M sold.

Based on aggregated 13F filings for Q2 2014.